276 related articles for article (PubMed ID: 15615494)
1. The OPG/RANKL/RANK system in metabolic bone diseases.
Hofbauer LC; Kühne CA; Viereck V
J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):268-75. PubMed ID: 15615494
[TBL] [Abstract][Full Text] [Related]
2. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC
Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
[TBL] [Abstract][Full Text] [Related]
3. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
[TBL] [Abstract][Full Text] [Related]
4. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D
Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054
[TBL] [Abstract][Full Text] [Related]
5. Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells.
Saunders MM; Taylor AF; Du C; Zhou Z; Pellegrini VD; Donahue HJ
J Biomech; 2006; 39(8):1419-27. PubMed ID: 15953606
[TBL] [Abstract][Full Text] [Related]
6. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.
Hofbauer LC; Shui C; Riggs BL; Dunstan CR; Spelsberg TC; O'Brien T; Khosla S
Biochem Biophys Res Commun; 2001 Jan; 280(1):334-9. PubMed ID: 11162519
[TBL] [Abstract][Full Text] [Related]
7. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
[TBL] [Abstract][Full Text] [Related]
8. [New paradigms in the regulation of bone metabolism].
Rosa-Rañal M; de la Cruz DA; Lorena-Rubio Y; Larrea F
Rev Invest Clin; 2001; 53(4):362-9. PubMed ID: 11599485
[TBL] [Abstract][Full Text] [Related]
9. Heritable disorders of the RANKL/OPG/RANK signaling pathway.
Whyte MP; Mumm S
J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):254-67. PubMed ID: 15615493
[TBL] [Abstract][Full Text] [Related]
10. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
11. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
Humphrey EL; Williams JH; Davie MW; Marshall MJ
Bone; 2006 May; 38(5):652-61. PubMed ID: 16298558
[TBL] [Abstract][Full Text] [Related]
12. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
13. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
14. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
[TBL] [Abstract][Full Text] [Related]
15. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
[TBL] [Abstract][Full Text] [Related]
16. RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis.
Ritchlin CT; Schwarz EM; O'Keefe RJ; Looney RJ
J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):276-84. PubMed ID: 15615495
[TBL] [Abstract][Full Text] [Related]
17. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
18. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F
Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158
[TBL] [Abstract][Full Text] [Related]
20. RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T; Nakashima T; Hiroshi N; Penninger JM
Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]